OncoMatch/Clinical Trials/NCT05748145

Metronidazole as Preoperative Therapy in CRC / FusoMetro-001

Is NCT05748145 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Metronidazole Oral for colorectal cancer.

Phase 2RecruitingOncology Institute of Southern SwitzerlandNCT05748145Data as of May 2026

Treatment: Metronidazole Oral — The proposed proof-of concept trial aims at determining the effectiveness of metronidazole in decreasing the Fusobacterium nucleatum load in tissues and possibly on its detrimental effects on tumor cells and tumor microenvironment.

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: anticancer treatment

Any previous anticancer treatment prior resection

Cannot have received: oral or parenteral antibiotic therapy

Oral or parenteral antibiotic therapy within the six weeks prior to enrolment

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify